Oxybutynin Chloride Tablet
Product Images NDC 82868-047

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 82868-047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (82868 047 30 Rev A 02 24)

This is a description of Oxybutynin Chloride tablets. Each tablet contains 8 mg of Oxybutynin Chloride. The tablets come in a package of 30 tablets and are intended for prescription use only. The tablets should be stored at room temperature and kept out of reach of children. They have been repackaged from a specific product number by Northwind Pharmaceuticals in Indianapolis, IN. The expiration date listed is "000010000" with Lot number "0000000000".*

FDA Label Image

Structural Formula (Figure 1 Structure)

FDA Label Image

Table 1 (Figure 2 Table1)

This -generated text includes information about the parameters G, Toa, AUC, and UGy for two different units - R-Oybutynin and S-Ouybutynin. The values provided are for G (ng/ml), Toa (1), AUC (ng=h/mL), and UGy (ng=ml). The data shows numerical values and their respective units for each parameter, allowing for a comparison between R-Oybutynin and S-Ouybutynin.*

FDA Label Image

Figure 1 (Figure 3 Figure1)

FDA Label Image

Table 2 (Figure 4 Table2)

This text appears to show data related to different compounds and their concentrations. It includes measurements for R-Oxybutynin, S-Oxybutynin, R-Desethyloxybutynin, and S-Desethyloxybutynin in units of g/mL. Additionally, there are values listed under 'Toa' and 'AUC (ng*min/mL)' for each compound. The text mentions reflected data and the abbreviation "Cgfo," implying some form of analysis or comparison.*

FDA Label Image

Figure 2 (Figure 5 Figure2)

FDA Label Image

Table 3 (Figure 6 Table3)

This text provides a list of potential adverse events associated with the drug Oxybutynin Chioride. Some of the reported adverse events include urinary tract infection, insomnia, dizziness, blurred vision, dry mouth, constipation, and urinary retention. The percentages indicate the frequency of these events among users.*

FDA Label Image

Kvk Logo (Figure 7 Company Logo)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.